These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26415700)

  • 1. Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics.
    Calcagno A; Montrucchio C; Capetti A; Guaraldi G; Cenderello G; Calza L; Lanzafame M; Marinaro L; Tettoni MC; Trentini L; D'Avolio A; Di Perri G; Bonora S
    Curr HIV Res; 2016; 14(1):54-60. PubMed ID: 26415700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.
    Marinaro L; Calcagno A; Ripamonti D; Cenderello G; Pirriatore V; Trentini L; Salassa B; Bramato C; Orofino G; D'Avolio A; Rizzi M; Di Perri G; Rusconi S; Bonora S
    J Clin Virol; 2017 Feb; 87():30-36. PubMed ID: 27992788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.
    Reliquet V; Chirouze C; Allavena C; Muret P; Peytavin G; André-Garnier E; Bettinger D; Ferré V; Hoen B; Raffi F
    Antivir Ther; 2014; 19(1):117-23. PubMed ID: 24145365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/mL.
    Madeddu G; Rusconi S; Cozzi-Lepri A; Di Giambenedetto S; Bonora S; Carbone A; De Luca A; Gianotti N; Di Biagio A; Antinori A;
    Infection; 2017 Aug; 45(4):521-528. PubMed ID: 28477212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
    João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
    Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Raltegravir-Darunavir/Ritonavir Combination in Virologically Suppressed HIV-1-Infected Patients on Antiretroviral Therapy Including a Ritonavir-Boosted Protease Inhibitor Plus Two Nucleoside/Nucleotide Reverse Transcriptase Inhibitors.
    Calza L; Danese I; Magistrelli E; Colangeli V; Manfredi R; Bon I; Re MC; Conti M; Viale P
    HIV Clin Trials; 2016 Feb; 17(1):38-47. PubMed ID: 26728706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.
    Rizzardo S; Lanzafame M; Lattuada E; Bragantini D; Nicolè S; Calza L; Tacconelli E
    Int J STD AIDS; 2019 Apr; 30(5):467-471. PubMed ID: 30999834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
    Katlama C; Assoumou L; Valantin MA; Soulié C; Martinez E; Béniguel L; Bouchaud O; Raffi F; Molina JM; Fellahi S; Peytavin G; Marcelin AG; Kolta S; Capeau J; Gibowski S; Cardon F; Reynes J; Costagliola D;
    J Antimicrob Chemother; 2019 Sep; 74(9):2742-2751. PubMed ID: 31269208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of raltegravir-containing regimens in antiretroviral-naïve and -experienced individuals in routine clinical practice.
    Jaeckle M; Khaykin P; Haberl A; De Leuw P; Schüttfort G; Stephan C; Wolf T
    Int J STD AIDS; 2016 Nov; 27(13):1170-1179. PubMed ID: 26429890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical Review: Review of the Efficacy, Safety, and Pharmacokinetics of Raltegravir in Pregnancy.
    Maliakkal A; Walmsley S; Tseng A
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):153-61. PubMed ID: 27183177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study of dual therapy with raltegravir 400 mg twice daily and Darunavir/Ritonavir 800/100 mg once daily in HIV-1-infected patients.
    Martínez-Rebollar M; Muñoz A; Pérez I; Hidalgo S; Brunet M; Laguno M; González A; Calvo M; Loncà M; Blanco JL; Martínez E; Gatell JM; Mallolas J
    Ther Drug Monit; 2013 Aug; 35(4):552-6. PubMed ID: 23851911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily dosing of nevirapine in HAART.
    Clotet B
    J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
    Patel N; Abdelsayed S; Veve M; Miller CD
    Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
    Nachman S; Alvero C; Teppler H; Homony B; Rodgers AJ; Graham BL; Fenton T; Frenkel LM; Browning RS; Hazra R; Wiznia AA;
    Lancet HIV; 2018 Dec; 5(12):e715-e722. PubMed ID: 30527329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors.
    Loulergue P; Merad M; Coriat R; Ducreux M; Planchard D; Boige V; Le Cesne A; Gregory TM; Poinsignon V; Paci A; Mir O
    Invest New Drugs; 2017 Apr; 35(2):247-249. PubMed ID: 27838867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.
    Ananworanich J; Gorowara M; Avihingsanon A; Kerr SJ; van Heesch N; Khongpetch C; Uanithirat A; Hill A; Ruxrungtham K; Burger DM;
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1892-8. PubMed ID: 22252825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
    Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
    Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.